Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis

Bella Zeisler, Trudy Lerer, James Markowitz, David MacK, Anne Griffiths, Athos Bousvaros, David Keljo, Joel Rosh, Jonathan Evans, Michael Kappelman, Anthony Otley, Marsha Kay, Andrew Grossman, Shehzad Saeed, Ryan Carvalho, Maria Oliva-Hemker, William Faubion, Boris Sudel, Marian Pfefferkorn, Farhat Ashai-Khan & 2 others Neal Leleiko, Jeffrey Hyams

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

OBJECTIVES: Despite a paucity of published supporting data, 5-aminosalicylate (5-ASA) use in pediatric ulcerative colitis (UC) is common. The present study describes the use and outcome of a large multicenter inception cohort of children with UC treated with 5-ASA. METHODS: Data were obtained from the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry, a prospective North American observational study of children newly diagnosed as having inflammatory bowel disease ages 16 years or younger. Patient data are recorded at diagnosis, 30 days, and then quarterly. Patients are managed by physician dictate, not protocol. Disease activity is classified by physician global assessment. The primary outcome examined was corticosteroid (CS) free, inactive UC at 1 year following initiation of 5-ASA within 30 days of diagnosis (with or without concomitant CS use) without the need for rescue therapy (immunomodulators, biologics, or colectomy). RESULTS: Study subjects included 213 patients newly diagnosed as having UC who received oral 5-ASA compounds (115 of whom also received CS) during the first 30 days after diagnosis, and no other oral therapies for the treatment of UC. Of these 213 patients, 86 (40%) were CS free and physician global assessment inactive at 1 year without rescue. Outcome was not associated with disease severity at diagnosis, demographic or laboratory factors examined, or initial dose of 5-ASA used. CONCLUSIONS: Forty percent of children taking 5-ASA as primary maintenance therapy at diagnosis are in CS-free remission after 1 year of treatment. Further pediatric studies will be needed to address whether increased adherence and/or higher dosing schedules will improve outcomes.

Original languageEnglish (US)
Pages (from-to)12-18
Number of pages7
JournalJournal of pediatric gastroenterology and nutrition
Volume56
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Mesalamine
Ulcerative Colitis
Adrenal Cortex Hormones
Physicians
Therapeutics
Pediatrics
Biological Therapy
Colectomy
Immunologic Factors
Inflammatory Bowel Diseases
Observational Studies
Registries
Appointments and Schedules
Demography
Research

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Cite this

Zeisler, Bella ; Lerer, Trudy ; Markowitz, James ; MacK, David ; Griffiths, Anne ; Bousvaros, Athos ; Keljo, David ; Rosh, Joel ; Evans, Jonathan ; Kappelman, Michael ; Otley, Anthony ; Kay, Marsha ; Grossman, Andrew ; Saeed, Shehzad ; Carvalho, Ryan ; Oliva-Hemker, Maria ; Faubion, William ; Sudel, Boris ; Pfefferkorn, Marian ; Ashai-Khan, Farhat ; Leleiko, Neal ; Hyams, Jeffrey. / Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. In: Journal of pediatric gastroenterology and nutrition. 2013 ; Vol. 56, No. 1. pp. 12-18.
@article{9aa184fd7f3046d3b6df0ad6ca794a44,
title = "Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis",
abstract = "OBJECTIVES: Despite a paucity of published supporting data, 5-aminosalicylate (5-ASA) use in pediatric ulcerative colitis (UC) is common. The present study describes the use and outcome of a large multicenter inception cohort of children with UC treated with 5-ASA. METHODS: Data were obtained from the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry, a prospective North American observational study of children newly diagnosed as having inflammatory bowel disease ages 16 years or younger. Patient data are recorded at diagnosis, 30 days, and then quarterly. Patients are managed by physician dictate, not protocol. Disease activity is classified by physician global assessment. The primary outcome examined was corticosteroid (CS) free, inactive UC at 1 year following initiation of 5-ASA within 30 days of diagnosis (with or without concomitant CS use) without the need for rescue therapy (immunomodulators, biologics, or colectomy). RESULTS: Study subjects included 213 patients newly diagnosed as having UC who received oral 5-ASA compounds (115 of whom also received CS) during the first 30 days after diagnosis, and no other oral therapies for the treatment of UC. Of these 213 patients, 86 (40{\%}) were CS free and physician global assessment inactive at 1 year without rescue. Outcome was not associated with disease severity at diagnosis, demographic or laboratory factors examined, or initial dose of 5-ASA used. CONCLUSIONS: Forty percent of children taking 5-ASA as primary maintenance therapy at diagnosis are in CS-free remission after 1 year of treatment. Further pediatric studies will be needed to address whether increased adherence and/or higher dosing schedules will improve outcomes.",
author = "Bella Zeisler and Trudy Lerer and James Markowitz and David MacK and Anne Griffiths and Athos Bousvaros and David Keljo and Joel Rosh and Jonathan Evans and Michael Kappelman and Anthony Otley and Marsha Kay and Andrew Grossman and Shehzad Saeed and Ryan Carvalho and Maria Oliva-Hemker and William Faubion and Boris Sudel and Marian Pfefferkorn and Farhat Ashai-Khan and Neal Leleiko and Jeffrey Hyams",
year = "2013",
month = "1",
day = "1",
doi = "10.1097/MPG.0b013e31826ac41a",
language = "English (US)",
volume = "56",
pages = "12--18",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Zeisler, B, Lerer, T, Markowitz, J, MacK, D, Griffiths, A, Bousvaros, A, Keljo, D, Rosh, J, Evans, J, Kappelman, M, Otley, A, Kay, M, Grossman, A, Saeed, S, Carvalho, R, Oliva-Hemker, M, Faubion, W, Sudel, B, Pfefferkorn, M, Ashai-Khan, F, Leleiko, N & Hyams, J 2013, 'Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis', Journal of pediatric gastroenterology and nutrition, vol. 56, no. 1, pp. 12-18. https://doi.org/10.1097/MPG.0b013e31826ac41a

Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. / Zeisler, Bella; Lerer, Trudy; Markowitz, James; MacK, David; Griffiths, Anne; Bousvaros, Athos; Keljo, David; Rosh, Joel; Evans, Jonathan; Kappelman, Michael; Otley, Anthony; Kay, Marsha; Grossman, Andrew; Saeed, Shehzad; Carvalho, Ryan; Oliva-Hemker, Maria; Faubion, William; Sudel, Boris; Pfefferkorn, Marian; Ashai-Khan, Farhat; Leleiko, Neal; Hyams, Jeffrey.

In: Journal of pediatric gastroenterology and nutrition, Vol. 56, No. 1, 01.01.2013, p. 12-18.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis

AU - Zeisler, Bella

AU - Lerer, Trudy

AU - Markowitz, James

AU - MacK, David

AU - Griffiths, Anne

AU - Bousvaros, Athos

AU - Keljo, David

AU - Rosh, Joel

AU - Evans, Jonathan

AU - Kappelman, Michael

AU - Otley, Anthony

AU - Kay, Marsha

AU - Grossman, Andrew

AU - Saeed, Shehzad

AU - Carvalho, Ryan

AU - Oliva-Hemker, Maria

AU - Faubion, William

AU - Sudel, Boris

AU - Pfefferkorn, Marian

AU - Ashai-Khan, Farhat

AU - Leleiko, Neal

AU - Hyams, Jeffrey

PY - 2013/1/1

Y1 - 2013/1/1

N2 - OBJECTIVES: Despite a paucity of published supporting data, 5-aminosalicylate (5-ASA) use in pediatric ulcerative colitis (UC) is common. The present study describes the use and outcome of a large multicenter inception cohort of children with UC treated with 5-ASA. METHODS: Data were obtained from the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry, a prospective North American observational study of children newly diagnosed as having inflammatory bowel disease ages 16 years or younger. Patient data are recorded at diagnosis, 30 days, and then quarterly. Patients are managed by physician dictate, not protocol. Disease activity is classified by physician global assessment. The primary outcome examined was corticosteroid (CS) free, inactive UC at 1 year following initiation of 5-ASA within 30 days of diagnosis (with or without concomitant CS use) without the need for rescue therapy (immunomodulators, biologics, or colectomy). RESULTS: Study subjects included 213 patients newly diagnosed as having UC who received oral 5-ASA compounds (115 of whom also received CS) during the first 30 days after diagnosis, and no other oral therapies for the treatment of UC. Of these 213 patients, 86 (40%) were CS free and physician global assessment inactive at 1 year without rescue. Outcome was not associated with disease severity at diagnosis, demographic or laboratory factors examined, or initial dose of 5-ASA used. CONCLUSIONS: Forty percent of children taking 5-ASA as primary maintenance therapy at diagnosis are in CS-free remission after 1 year of treatment. Further pediatric studies will be needed to address whether increased adherence and/or higher dosing schedules will improve outcomes.

AB - OBJECTIVES: Despite a paucity of published supporting data, 5-aminosalicylate (5-ASA) use in pediatric ulcerative colitis (UC) is common. The present study describes the use and outcome of a large multicenter inception cohort of children with UC treated with 5-ASA. METHODS: Data were obtained from the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry, a prospective North American observational study of children newly diagnosed as having inflammatory bowel disease ages 16 years or younger. Patient data are recorded at diagnosis, 30 days, and then quarterly. Patients are managed by physician dictate, not protocol. Disease activity is classified by physician global assessment. The primary outcome examined was corticosteroid (CS) free, inactive UC at 1 year following initiation of 5-ASA within 30 days of diagnosis (with or without concomitant CS use) without the need for rescue therapy (immunomodulators, biologics, or colectomy). RESULTS: Study subjects included 213 patients newly diagnosed as having UC who received oral 5-ASA compounds (115 of whom also received CS) during the first 30 days after diagnosis, and no other oral therapies for the treatment of UC. Of these 213 patients, 86 (40%) were CS free and physician global assessment inactive at 1 year without rescue. Outcome was not associated with disease severity at diagnosis, demographic or laboratory factors examined, or initial dose of 5-ASA used. CONCLUSIONS: Forty percent of children taking 5-ASA as primary maintenance therapy at diagnosis are in CS-free remission after 1 year of treatment. Further pediatric studies will be needed to address whether increased adherence and/or higher dosing schedules will improve outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84872290627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872290627&partnerID=8YFLogxK

U2 - 10.1097/MPG.0b013e31826ac41a

DO - 10.1097/MPG.0b013e31826ac41a

M3 - Article

VL - 56

SP - 12

EP - 18

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -